When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to what analysts expected but weren’t enough to placate investors.
When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to what analysts expected but weren’t enough to placate investors.